GNH USA

Europe — EMA

Mitoxantrone Accord

GNH USA supplies Mitoxantrone Accord (Mitoxantrone), an antineoplastic for acute leukemia, metastatic breast and prostate cancer. Request a quote now.

Mitoxantrone

Request sourcing

1
Pack/s

What is Mitoxantrone?

Mitoxantrone, the active ingredient in Mitoxantrone Accord, is an anthracenedione presented as an injectable solution for intravenous use. It treats acute myeloid leukemia, acute lymphoblastic leukemia, metastatic breast cancer, and prostate cancer in adult patients.

GNH USA supplies Mitoxantrone Accord as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide.

What is Mitoxantrone used for?

Mitoxantrone is used in hematologic malignancies and solid tumors where DNA synthesis is targeted.

Acute Myeloid Leukemia: induces remission in adult patients. Acute Lymphoblastic Leukemia: provides cytoreduction in relapsed disease. Metastatic Breast Cancer: offers disease control in hormone‑refractory cases. Prostate Cancer: used in hormone‑refractory metastatic disease.

What are the side effects of Mitoxantrone?

Mitoxantrone may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Fatigue: generalized tiredness during treatment. - Myelosuppression: reduced white blood cells, red cells, and platelets. - Alopecia: temporary hair loss.

Serious or Rare Side Effects: - Cardiotoxicity: potential decline in cardiac function. - Severe infection: due to profound neutropenia. - Secondary leukemia: rare development of a new hematologic malignancy.

What precautions apply to Mitoxantrone?

Before initiating therapy, clinicians should assess baseline organ function and monitor patients closely.

Monitor cardiac function: baseline and periodic ejection fraction assessment. Assess blood counts: regular CBC to detect myelosuppression. Evaluate liver function: monitor transaminases before and during therapy. Avoid use in patients with known hypersensitivity to anthracenediones. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Mitoxantrone interact with?

Mitoxantrone can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Concurrent use with other cardiotoxic agents (e.g., anthracyclines) increases risk of heart damage. - Co‑administration with strong CYP2C9 inhibitors may raise plasma levels. - Combination with myelosuppressive chemotherapy heightens bone‑marrow toxicity.

Moderate Interactions (Monitor Closely): - Use with live vaccines may reduce vaccine efficacy. - Concomitant use of anticoagulants may increase bleeding risk. - Drugs affecting renal clearance may require dose adjustment.

Frequently asked questions

What conditions is Mitoxantrone Accord used for?+
Mitoxantrone Accord is indicated for the treatment of acute myeloid leukemia, acute lymphoblastic leukemia, metastatic breast cancer, and hormone‑refractory metastatic prostate cancer in adult patients. It is administered as part of a chemotherapy regimen under the supervision of an oncologist.
How does mitoxantrone work to treat cancer?+
Mitoxantrone intercalates into DNA and stabilizes the topoisomerase II‑DNA complex, preventing the re‑ligation of DNA strands. This action creates double‑strand breaks, leading to apoptosis of rapidly dividing tumor cells. The drug also generates free radicals that add to its cytotoxic effect.
What is the usual dose of Mitoxantrone Accord?+
The dose of Mitoxantrone Accord is individualized by the prescribing oncologist based on the specific cancer type, disease stage, patient weight, renal and hepatic function, and prior treatment history. Only a qualified healthcare professional should determine the appropriate dosing schedule.
Is Mitoxantrone Accord safe during pregnancy or breastfeeding?+
The safety of mitoxantrone in pregnancy and lactation has not been established. It is generally contraindicated in pregnant or nursing women because of potential fetal toxicity and excretion in breast milk. Women of child‑bearing potential should use effective contraception during treatment and for a period afterward as advised by their physician.
How do I order Mitoxantrone Accord from GNH USA?+
To place an order, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and required import documentation.
How does Mitoxantrone Accord compare with other antineoplastic agents?+
Mitoxantrone belongs to the anthracenedione class and differs from anthracyclines such as doxorubicin in its chemical structure and toxicity profile. It is often chosen when a non‑anthracycline option is preferred, offering similar efficacy in certain leukemias and solid tumors but with a distinct risk of cardiotoxicity and secondary leukemia.
What are the storage and handling requirements for Mitoxantrone Accord?+
Mitoxantrone Accord should be stored at 2‑8 °C in a refrigerator, protected from light. The solution must not be frozen or shaken vigorously. Keep the vial in its original packaging until use to maintain stability and sterility.
How is Mitoxantrone Accord administered to patients?+
The medication is supplied as an injectable solution for intravenous infusion. It is typically diluted in a compatible IV fluid and administered over a prescribed period, often ranging from several minutes to an hour, under close clinical monitoring for infusion‑related reactions.
What are the most serious risks associated with Mitoxantrone Accord?+
The most serious adverse events include cardiotoxicity, which can lead to irreversible heart failure, severe myelosuppression that may cause life‑threatening infections or bleeding, and the rare possibility of therapy‑related secondary leukemia. Patients should be monitored regularly for cardiac function and blood counts.
Who should not receive Mitoxantrone Accord?+
Patients with known hypersensitivity to mitoxantrone or other anthracenediones, those with pre‑existing severe cardiac disease, uncontrolled infections, or significant bone‑marrow failure should not receive this drug. It is also contraindicated in pregnant or nursing women unless the benefits outweigh the risks.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Mitoxantrone
Route
Intravenous Use
Manufacturer
Accord Healthcare France Sas
Origin
EU

Related products

Mitoxan

Mitoxan

Mitoxantrone

Medicamerc S.A
EU
Mitoxantron "ebewe"

Mitoxantron "ebewe"

Mitoxantrone

Ebewe Pharma
EU
Mitoxantron Accord

Mitoxantron Accord

Mitoxantrone

Accord Healthcare B.V.
EU
Mitoxantron Ebewe

Mitoxantron Ebewe

Mitoxantrone

Ebewe Pharma
EU